1. Inicio
  2. Proyectos y Estudios
  3. A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Datos básicos

ENSAYO CLÍNICO Finan. Competitiva DS6000-109 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2024

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

DAIICHI SANKYO, INC. C/O SYNEOS HEALTH UK LTD

Compartir